NEW YORK (GenomeWeb News) – Cancer care firm N-of-One today announced a deal with Foundation Medicine to translate sequencing data into clinically relevant information.

Under the terms of the agreement, Foundation will identify potential biomarkers using its sequencing and analytic capabilities on patient tumor samples. N-of-One will then use its PrecisionWorks platform to translate data from Foundation to link molecular changes with current information about relevant target therapies and clinical trials that may be used to guide treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.